Psychosis News and Research

RSS

Psychosis means abnormal condition of the mind, and is a generic psychiatric term for a mental state often described as involving a "loss of contact with reality". People suffering from psychosis are said to be ''psychotic.''

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Prevalence of bipolar disorder

Bipolar disorder is a psychiatric disorder that swings between depression and mania. It strikes early and can cause lifelong disability. Reports show that it is chronically undertreated in many low-income countries.

7 Mar 2011

Exercise can reduce cannabis use in persons who don't want to stop

Vanderbilt researchers are studying heavy users of marijuana to help understand what exercise does for the brain, contributing to a field of research that uses exercise as a modality for prevention and treatment.

4 Mar 2011

Marijuana and psychosis linked in a study

...

3 Mar 2011

Research: Gene mutation linked to schizophrenia may aid in new drug development

In a major advance for schizophrenia research, an international team of scientists led by the University of California, San Diego School of Medicine and involving Trinity College Dublin researchers has identified a gene mutation strongly linked to schizophrenia that may be an important new target for the development of drug therapies.

24 Feb 2011

Energy drink induced psychosis in mentally ill

A new study that has appeared in the latest publication of the Medical Journal of Australia has shown that the mentally ill should avoid energy drinks as they may result in a trigger of psychosis.

21 Feb 2011

PsychoGenics establishes alliance with KineMed to provide specialized neurogenesis services

PsychoGenics today announced the establishment of an alliance with KineMed, to provide specialized neurogenesis services to complement PsychoGenics' in vivo testing capabilities.

15 Feb 2011

New study: Cannabis use significantly hastens onset of psychotic illness

A new study has provided the first conclusive evidence that cannabis use significantly hastens the onset of psychotic illnesses during the critical years of brain development - with possible life-long consequences.

9 Feb 2011

Cannabis use accelerates psychosis in the young: Study

A new study has shown that cannabis use can hasten the onset of schizophrenia by several years. The study included data from 20,000 patients with a psychotic illness and found those who smoked cannabis were diagnosed almost three years ahead of those who did not use the drug. The research is published in the journal Archives of General Psychiatry.

8 Feb 2011

Schizophrenia patients who consume antipsychotics appear to lose small amount of brain tissue

Patients with schizophrenia who take antipsychotic medications appear to lose a small but measurable amount of brain tissue over time, according to a report in the February issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Feb 2011

Study: Cannabis use appears to be linked with earlier onset of psychotic illness

Cannabis use appears to be associated with an earlier onset of psychotic illness, according to a meta-analysis of previously published studies posted online today that will appear in the June print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Feb 2011

Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia

Targacept, Inc. today announced positive top-line results from a Phase 2 clinical proof of concept trial to assess TC-5619 as an augmentation therapy to improve cognition in patients with schizophrenia.

20 Jan 2011

Biological Psychiatry publishes special issue focusing on postmortem studies of psychosis

Biological Psychiatry is proud to announce this week's publication of a special issue focusing on postmortem studies of psychosis. This special issue showcases the use of human brains postmortem to study psychiatric disorders, focusing on schizophrenia. The review articles highlight the benefits, achievements, problems, and perhaps most importantly, the future of postmortem research.

18 Jan 2011

Mithridion secures commitments of $1.25 million in new funding

Mithridion, Inc., a privately-owned clinical stage drug development company focusing on serious Central Nervous System disorders, including Alzheimer's disease, announces that it has secured commitments of $1.25 million in new funding.

11 Jan 2011

ACADIA raises $15 million through private placement

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has entered into a securities purchase agreement for a private placement financing with a select group of institutional investors, including New Enterprise Associates and Venrock.

10 Jan 2011

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

Sunovion Pharmaceuticals Inc. today announced the results of the PEARL 3 study, the third phase 3 worldwide clinical trial of Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with schizophrenia. In this six-week, placebo-controlled trial, both fixed doses of LATUDA 80 and 160 mg once-daily, demonstrated statistically significant improvement in symptoms of schizophrenia versus placebo across both primary and secondary efficacy measures.

9 Dec 2010

People suffering psychotic disorders 12 times more likely to commit suicide

People with psychotic disorders, such as schizophrenia or bipolar disorder, are 12 times more likely to commit suicide than average, according to research released today by King's Health Partners.

7 Dec 2010

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Schizophrenia is a chronic and disabling brain disorder that affects 1 percent of the U.S. population and results in substantial medical and societal costs, in particular from use of health-care resources. It also can have devastating health-related and social effects on people with the disease, their families and caregivers.

20 Nov 2010

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Santarus, Inc., a specialty biopharmaceutical company, today announced the commercial U.S. launch of CYCLOSET (bromocriptine mesylate) tablets. CYCLOSET is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.

15 Nov 2010

Phase III study suggests CYCLOSET tablets improve glycemic control

Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.

4 Nov 2010

Psychosis News and Research

Further Reading

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Prevalence of bipolar disorder

Exercise can reduce cannabis use in persons who don't want to stop

Marijuana and psychosis linked in a study

Research: Gene mutation linked to schizophrenia may aid in new drug development

Energy drink induced psychosis in mentally ill

PsychoGenics establishes alliance with KineMed to provide specialized neurogenesis services

New study: Cannabis use significantly hastens onset of psychotic illness

Cannabis use accelerates psychosis in the young: Study

Schizophrenia patients who consume antipsychotics appear to lose small amount of brain tissue

Study: Cannabis use appears to be linked with earlier onset of psychotic illness

Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia

Biological Psychiatry publishes special issue focusing on postmortem studies of psychosis

Mithridion secures commitments of $1.25 million in new funding

ACADIA raises $15 million through private placement

Sunovion reports results of Latuda third phase 3 worldwide clinical trial for schizophrenia

People suffering psychotic disorders 12 times more likely to commit suicide

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Phase III study suggests CYCLOSET tablets improve glycemic control

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News